AWM
FDMT icon

Able Wealth Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Able Wealth Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-9
Closed -$182 – 245
2023
Q4 		$182 Buy
+9
New +$118 ﹤0.01% 585

Other funds holding FDMT

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Able Wealth Management's FDMT Position: Q1 2024 in Review

Able Wealth Management sold out of 4D Molecular Therapeutics (FDMT) in Q1 2024, closing a stake of 9 shares — an estimated $182 sold.

Able Wealth Management first reported a position in FDMT in Q4 2023 and held it in 1 quarter. The position peaked at $182 in Q4 2023. 147 funds tracked by Wall St. Rank hold FDMT as of Q1 2024.

  • Able Wealth Management reported no remaining 4D Molecular Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Able Wealth Management sold 9 4D Molecular Therapeutics shares in Q1 2024, an estimated $182.
  • Able Wealth Management first reported a position in 4D Molecular Therapeutics in Q4 2023 and held it in 1 quarter.
  • Able Wealth Management's 4D Molecular Therapeutics position peaked at $182 in Q4 2023.
  • 147 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2024.

Based on Able Wealth Management's 13F filing for Q1 2024, filed 1 Nov 2024.